%PDF-1.4
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2017-10-16T15:38:14+05:30
2017-10-16T15:38:16+05:30
2017-10-16T15:38:16+05:30
Adobe InDesign CS6 (Macintosh)
uuid:47b9e5da-f555-054d-a048-8a38185ca8ff
xmp.did:01801174072068118DBB881A9EDFAAFA
xmp.id:0680117407206811822AAA8E3ACE1529
proof:pdf
converted
from application/x-indesign to application/pdf
Adobe InDesign CS6 (Macintosh)
/
2017-10-16T15:38:14+05:30
xmp.iid:0280117407206811822AAA8E3ACE1529
xmp.did:01801174072068118DBB881A9EDFAAFA
xmp.did:01801174072068118DBB881A9EDFAAFA
default
application/pdf
Adobe PDF Library 10.0.1
False
endstream
endobj
5 0 obj
<>
endobj
3 0 obj
<>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
8 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
11 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
37 0 obj
<>stream
q
/GS0 gs
/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
11 0 0 11 573.9999 54.4294 Tm
(15)Tj
ET
q
0 g
/GS0 gs
/Fm1 Do
Q
0 0 0 1 K
q 1 0 0 1 45 508.2417 cm
0 0 m
258 0 l
S
Q
q 1 0 0 1 45 365.2417 cm
0 0 m
258 0 l
S
Q
BT
/TT0 1 Tf
-0.005 Tc 0.183 Tw 11 0 0 11 45 697.9917 Tm
(4.)Tj
/Span<>> BDC
( )Tj
EMC
1.909 0 Td
[(Most common )0.5(adverse )0.5(ef)18.3(fects )0.5(noted )0.5(are )0.5(head)]TJ
/C2_0 1 Tf
0 Tc 0 Tw <0010>Tj
/TT0 1 Tf
-0.005 Tc -0.06 Tw 0 -1.182 TD
(ache, nausea/vomiting, hypotension, and anemia.)Tj
0 Tc 0.321 Tw -1.909 -1.773 Td
(5.)Tj
/Span<>> BDC
( )Tj
EMC
1.909 0 Td
(The most serious adverse events are throm)Tj
/C2_0 1 Tf
0 Tw <0010>Tj
0 -1.182 TD
[<004500520048005000450052004F004C00460003>-259.6<004800590048005100570056000F0003>-258.6<004C00510046004F00580047004C0051004A0003>-259.8<0056005700550052004E0048000F0003>-258.5<00530058004F00500052005100440055005C0003>]TJ
0 -1.182 TD
[<0048005000450052004F004C00560050000F0003>-196.9<0044005100470003>-196.3<002700390037>110.8<00110003>-196.1<003300440057004C00480051005700560003>-196.2<005A004C0057004B0003>-196.5<0057004B0055005200500045005200480050>]TJ
21.212 0 Td
<0010>Tj
/TT0 1 Tf
0.098 Tw -21.212 -1.182 Td
[(bolic )-0.8(events within )-0.6(three months were )-0.6(excluded )]TJ
0.172 Tw T*
[(from )0.5(the studies used for )0.5(product approval. Its )]TJ
/C2_0 1 Tf
0 Tw T*
[<00560044004900480057005C0003>19.4<00530055005200BF004F00480003>18.8<0044005000520051004A0003>18.8<0057004B004C00560003>19.3<005300440057004C0048005100570003>19<0053005200530058004F00440057004C005200510003>18.1<004C00560003>19.3<0051005200570003>]TJ
/TT0 1 Tf
0 -1.182 TD
(well studied, and it is generally avoided. )Tj
0.286 Tw -1.909 -1.773 Td
(6.)Tj
/Span<>> BDC
( )Tj
EMC
1.909 0 Td
[(Kcentra of)18.1(fers )0.6(a low volume, fast )0.8(method for )]TJ
0.219 Tw 0 -1.182 TD
[(rapid )-0.7(INR reversal )-0.6(and clinical )-1.1(hemostasis. Its )]TJ
/C2_0 1 Tf
0 Tw T*
[<004C005100460055004800440056004800470003>-37.5<0058005600480003>-36.6<005A004C004F004F0003>-37.3<0049005800550057004B004800550003>-36.7<0047004800BF005100480003>-37.1<004C005700560003>-36.6<00560044004900480057005C0003>-36.5<00530055005200BF004F00480003>]TJ
/TT0 1 Tf
T*
(and possibly identify other indications.)Tj
/TT1 1 Tf
10.25 0 0 10.25 45 489.7417 Tm
(Article citation:)Tj
/TT0 1 Tf
[( Ismail )55.2(A. Kcentra)]TJ
6.355 0 0 6.355 199.3606 493.6367 Tm
(\256)Tj
/C2_0 1 Tf
10.25 0 0 10.25 204.0431 489.7417 Tm
<0003000B0033005500520057004B0055005200500045004C00510003>Tj
/TT0 1 Tf
-15.516 -1.195 Td
(Complex Concentrate [Human]\):)Tj
14.339 0 Td
( its indications, side )Tj
-14.339 -1.195 Td
[(ef)18.1(fects, and contraindications. Southwest Respiratory )]TJ
0 -1.22 TD
[(and Critical Care Chronicles 2017;5\(21\):1)71.3(1\22615)]TJ
/TT1 1 Tf
0 -1.22 TD
(From:)Tj
/TT0 1 Tf
10.5 0 0 10.5 74.0383 440.2417 Tm
[( Department of Internal Medicine at )17.1(T)111(exas )17.9(T)111(ech )]TJ
/C2_0 1 Tf
-2.766 -1.19 Td
[<00380051004C0059004800550056004C0057005C0003002B00480044004F0057004B000300360046004C004800510046004800560003002600480051005700480055>53.3<000F0003002F00580045004500520046004E000F0003>18<0037>111<0048005B00440056>]TJ
/TT1 1 Tf
10.25 0 0 10.25 45 415.2417 Tm
(Submitted:)Tj
/TT0 1 Tf
10.5 0 0 10.5 98.5222 415.2417 Tm
( 4/6/2017)Tj
/TT1 1 Tf
10.25 0 0 10.25 45 402.7417 Tm
(Accepted:)Tj
/TT0 1 Tf
10.5 0 0 10.5 94.5533 402.7417 Tm
( 10/4/2017)Tj
/TT1 1 Tf
10.25 0 0 10.25 45 390.2417 Tm
(Reviewer: )Tj
/TT0 1 Tf
10.5 0 0 10.5 96.275 390.2417 Tm
(Catherine Jones MD)Tj
/C2_1 1 Tf
10.25 0 0 10.25 45 377.7417 Tm
<00260052005100C0004C0046005700560003005200490003004C0051005700480055004800560057001D>Tj
/TT0 1 Tf
( none)Tj
ET
q
0 0 630 810 re
W n
BT
/T1_1 1 Tf
13 0 0 13 327 695.808 Tm
(R)Tj
9.1 0 0 9.1 335.6709 695.808 Tm
(EFE)Tj
/Span<>> BDC
(R)Tj
EMC
(ENCES)Tj
ET
Q
BT
/T1_0 1 Tf
-0.03 Tc 0.03 Tw 10 0 0 10 327 670.808 Tm
[(1)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.175 Tw 1.3 0 Td
[(KCENTRA \(package inser)-19.7(t\). Kankak)9.8(ee, IL: CSL Behring; )]TJ
0 Tw 0 -1.2 TD
(2017.)Tj
/T1_0 1 Tf
-0.03 Tc 0.03 Tw -1.3 -1.2 Td
[(2)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.18 Tw 1.3 0 Td
[(Ageno )29.6(W)149.9(, Gallus )54.8(AS, )29.6(W)39.8(ittk)9.7(o)39.8(wsk)14.9(y )54.8(A, et al. Oral anticoag)]TJ
0 Tw (-)Tj
0.303 Tw T*
[(ulant therap)29.8(y: )54.9(Antithrombotic )49.7(Therap)29.9(y and Pre)24.9(v)14.9(ention of )]TJ
0.126 Tw T*
[(Thrombosis, )0.5(9th ed: )55.5(American )0.5(Colle)14.9(ge )0.5(of Chest )0.5(Ph)29.8(ysicians )]TJ
0.301 Tw T*
(Evidence-Based Clinical Practice Guidelines. Chest 2012 )Tj
0 Tw T*
[(F)49.8(eb;141\(2 Suppl\):e44S\226e88S.)]TJ
/T1_0 1 Tf
-0.03 Tc 0.03 Tw -1.3 -1.2 Td
[(3)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.303 Tw 1.3 0 Td
[(P)14.9(ande)14.9(y S, )49.3(Vyas GN)24.9(. )54.5(Adv)14.9(erse ef)25(fects of plasma transfu)]TJ
0 Tw (-)Tj
T*
(sion.)Tj
/Span<>> BDC
( )Tj
EMC
2.117 0 Td
[(T)34.9(ransfusion)]TJ
[( 2012 Ma)34.9(y; 52 Suppl 1:65S\22679S.)]TJ
/T1_0 1 Tf
-0.03 Tc 0.03 Tw -3.417 -1.2 Td
[(4)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.061 Tw 1.3 0 Td
[(Theusinger OM et al. P)39.8(oint of Care and F)59.8(actor Concentrate-)]TJ
0 Tw ( )Tj
0.329 Tw T*
[(Based )-54.9(Coagulation Algorithms. )]TJ
0.384 Tw 13.936 0 Td
[(T)34.9(ransfus Med Hemother)]TJ
0 Tw ( )Tj
-13.936 -1.2 Td
(2015 Mar;42\(2\):115\226121.)Tj
/T1_0 1 Tf
-0.03 Tc 0.03 Tw -1.3 -1.2 Td
[(5)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.044 Tw 1.3 0 Td
[(Schulman S, Bijster)-19.8(v)14.9(eld NR. )55.1(Anticoagulants and their re)25(v)14.8(er)]TJ
0 Tw 24.167 0 Td
(-)Tj
-24.167 -1.2 Td
[(sal. )49.8(T)35(ransfus Med Re)24.9(v 2007;21\(1\):37\22648.)]TJ
/T1_0 1 Tf
-0.03 Tc 0.03 Tw -1.3 -1.2 Td
[(6)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.084 Tw 1.3 0 Td
[(Sarode R, Milling )49.7(TJ)59.9(, Ref)-9.8(aai MA, et al. Ef\037cac)15(y and safety )]TJ
0.196 Tw T*
[(of a 4-f)-9.7(actor prothrombin comple)14.9(x concentrate in patients )]TJ
0.1 Tw T*
[(on vitamin K antagonists presenting with major b)19.8(leeding: a )]TJ
0.064 Tw T*
[(randomized)59.9(, plasma-controlled)59.9(, phase IIIb study)85(. Circulation )]TJ
0 Tw T*
(2013;128:1234\22643.)Tj
/T1_0 1 Tf
-0.03 Tc 0.03 Tw -1.3 -1.2 Td
[(7)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.127 Tw 1.3 0 Td
[(Goldstein JN)24.9(, Ref)-9.8(aai MA, Milling )50.1(TJ Hr)39.8(, et al. F)49.8(our)19.8(-f)-9.8(actor )]TJ
0.228 Tw T*
[(prothrombin comple)14.9(x concentrate v)14.9(ersus plasma for rapid )]TJ
0.306 Tw T*
[(vitamin K antagonist re)24.9(v)14.9(ersal in patients needing ur)17.8(gent )]TJ
0.228 Tw T*
[(sur)17.8(gical or in)39.8(v)24.9(asi)25(v)14.9(e inter)-19.8(v)14.9(entions: a phase 3b, open-label, )]TJ
0.09 Tw T*
[(non-inferiority)85(, randomized control study)85(. Lancet 2015 Ma)35(y )]TJ
0 Tw T*
(23;385\(9982\):2077\22687.)Tj
ET
endstream
endobj
23 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
BT
0 0 0 1 k
/GS0 gs
/T1_0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 45 54.1778 Tm
(The Southwest Respiratory and Critical Care Chronicles 2017;5\(21\):11\226\
15)Tj
ET
endstream
endobj
32 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
0 0 0 1 K
0.5 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 45 68.8957 cm
0 0 m
540 0 l
S
Q
10 M
q 1 0 0 1 45 740.2762 cm
0 0 m
540 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 45 751.5262 Tm
(Kcentra)Tj
4.96 0 0 4.96 72.5703 754.5662 Tm
(\256)Tj
8 0 0 8 76.2249 751.5262 Tm
( \(Prothrombin Complex Concentrate [Human]\): Its Indications, Side Effe\
cts, and Contraindications)Tj
/Span<>> BDC
( )Tj
EMC
60.986 0 Td
(Ismail)Tj
ET
endstream
endobj
41 0 obj
<>
endobj
42 0 obj
<>
endobj
43 0 obj
<>stream
H\͊0yC Bk[?`(|ɔ.d&_Ey*m7
YmLWuVl#tf~(Li L89nC3\a-7׀Mj->?Ѓe(\6bz|{O۔
w2-˘i
@d!>.lo>9ښډ,ayǼ#39>x $9eNNBuP|DNyߔMNJuR^5'zƀ1GĜ(W% 1(QY"7nQg3l_fM>}4hGfM.q+tm]oAg(1^+ .
endstream
endobj
44 0 obj
<>stream
HlUTUW>"EP)WXP+֠"A
aRTШQu4QьH!!bĘ2Xuou{=ghŐ`\gkIk{h^V@q=~`)n%b)9*